Verap 240mg prolonged release tablets

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

VERAPAMIL HYDROCHLORIDE

Available from:

Rowex Ltd

ATC code:

C08DA; C08DA01

INN (International Name):

VERAPAMIL HYDROCHLORIDE

Dosage:

240 milligram(s)

Pharmaceutical form:

Prolonged-release tablet

Prescription type:

Product subject to prescription which may be renewed (B)

Therapeutic area:

Phenylalkylamine derivatives; verapamil

Authorization status:

Marketed

Authorization date:

2001-10-05

Patient Information leaflet

PACKAGE LEAFLET: INFORMATION FOR THE USER
VERAP 120MG & 240MG PROLONGED RELEASE TABLETS
Verapamil Hydrochloride
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on
to others. It may harm them
even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor or pharmacist.
This includes any possible side effects
not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1. What Verap is and what it is used for
2. What you need to know before you take Verap
3. How to take Verap
4. Possible side effects
5. How to store Verap
6. Contents of the pack and other information
1 WHAT VERAP IS AND WHAT IT IS USED FOR
Verap belongs to a group of medicines called calcium antagonists. The
active substance in Verap is
verapamil hydrochloride.
Verap is used to:
• treat mild to moderate high blood pressure
• prevent a certain type of chest pain called angina pectoris
If you suffer from high blood pressure Verap works by relaxing blood
vessels, so that blood passes
through them more easily.
If you suffer from angina Verap works by improving blood supply to the
heart muscle which then
receives more oxygen and as a result chest pain is prevented.
Verapamil does not provide immediate
relief of chest pain from angina.
2 WHAT YOU NEED TO KNOW BEFORE YOU TAKE VERAP
DO NOT TAKE VERAP if you have any of the following conditions:
• allergic to verapamil or to any of the other ingredients of this
medicine (listed in section 6).
• insufficient blood supply to your tissues, e.g. caused by severe
heart troubles (cardiovascular
shock)
• very low blood pressure
• acute heart attack complicated by slow heartbeat
• second or third degree heart block or an electrical abnormality of
the heart (atrial
fibrillation/flutter) cau

Summary of Product characteristics

Health Products Regulatory Authority
16 March 2021
CRN00C63M
Page 1 of 14
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Verap 240mg prolonged release tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains Verapamil Hydrochloride 240.00 mg.
Excipient(s) with known effect: Each tablet contains lactose
monohydrate 8.84 mg and sodium 29.4mg.
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Prolonged release tablet
Green, oblong, biconvex, film‐coated prolonged release tablet with a
score notch on both sides. The score notch should not be
used to break the tablet.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
VERAP tablets are indicated for the treatment of mild to moderate
hypertension and coronary heart disease, i.e. prophylaxis of
myocardial ischemia and angina pectoris.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The dose of verapamil hydrochloride should be adjusted individually in
accordance with the severity of disease. Long‐standing
clinical experience shows that the average daily dose in all
indications is between 240 mg and 360 mg. The daily dose should
not exceed 480 mg on a long‐term basis, although a higher dose may
be used for a short period.
There is no limitation on the duration of use. Verapamil hydrochloride
should not be discontinued abruptly after long‐term use.
It is recommended to taper the dosage.
_Hypertension:_
The adult dose of 240 mg [1 tablet] in the morning is indicated
increasing if necessary after one week to 240 mg in the
morning and 240 mg in the evening with an interval of 12 hours.
_Elderly_
In elderly patients the initial dose is 120 mg in the morning,
increasing by 120 mg increments at weekly intervals according to
the patient’s response.
_Angina Pectoris:_
The usual dose is 120‐240 mg twice daily according to patient’s
response. It is recommended that low initial doses with upward
titration be used in new patients.
SPECIAL POPULATIONS
_Renal impairment_
Currently available data are described in